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76 AnnaStudy objective: We aim to prospectively validate the diagnostic accuracy of the recently developed 0-h/1-h algorithm,
using high-sensitivity cardiac troponin T (hs-cTnT) for the early rule-out and rule-in of acute myocardial infarction.
Methods: We enrolled patients presenting with suspected acute myocardial infarction and recent (<6 hours) onset of
symptoms to the emergency department in a global multicenter diagnostic study. Hs-cTnT (Roche Diagnostics) and
sensitive cardiac troponin I (Siemens Healthcare) were measured at presentation and after 1 hour, 2 hours, and 4 to 14
hours in a central laboratory. Patient triage according to the predeﬁned hs-cTnT 0-hour/1-hour algorithm (hs-cTnT below
12 ng/L and D1 hour below 3 ng/L to rule out; hs-cTnT at least 52 ng/L or D1 hour at least 5 ng/L to rule in; remaining
patients to the “observational zone”) was compared against a centrally adjudicated ﬁnal diagnosis by 2 independent
cardiologists (reference standard). The ﬁnal diagnosis was based on all available information, including coronary
angiography and echocardiography results, follow-up data, and serial measurements of sensitive cardiac troponin I,
whereas adjudicators remained blinded to hs-cTnT.
Results: Among 1,282 patients enrolled, acute myocardial infarction was the ﬁnal diagnosis for 213 (16.6%) patients.
Applying the hs-cTnT 0-hour/1-hour algorithm, 813 (63.4%) patients were classiﬁed as rule out, 184 (14.4%) were
classiﬁed as rule in, and 285 (22.2%) were triaged to the observational zone. This resulted in a negative predictive value
and sensitivity for acute myocardial infarction of 99.1% (95% conﬁdence interval [CI] 98.2% to 99.7%) and 96.7% (95%
CI 93.4% to 98.7%) in the rule-out zone (7 patients with false-negative results), a positive predictive value and speciﬁcity
for acute myocardial infarction of 77.2% (95% CI 70.4% to 83.0%) and 96.1% (95% CI 94.7% to 97.2%) in the rule-in
zone, and a prevalence of acute myocardial infarction of 22.5% in the observational zone.
Conclusion: The hs-cTnT 0-hour/1-hour algorithm performs well for early rule-out and rule-in of acute myocardial
infarction. [Ann Emerg Med. 2016;68:76-87.]
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INTRODUCTION
Background
Patients with symptoms suggestive of acute myocardial
infarction account for approximately 10% of all emergency
department (ED) consultations.1-3 The 12-lead ECG and
cardiac troponin (cTn) form the cornerstones for thedditional contributors in the TRAPID-AMI study is provided in
available online at http://www.annemergmed.com.
ls of Emergency Medicinediagnosis of acute myocardial infarction and complement
clinical assessment.1-3 A limitation of former-generation
cTn assays is the inability to detect low levels of cTn and
the associated need for prolonged serial sampling for 6 to
12 hours.1,2,4 Delays in diagnosing disease (rule-in delays)
hold back prompt use of evidence-based therapies.1,2
Delays in excluding acute myocardial infarction (rule-out
delays) interfere with evaluation of alternative diagnoses
and contribute to medical errors and costs associated with
crowding in the ED.5,6Volume 68, no. 1 : July 2016
Vo
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What is already known on this topic
Ruling out acute myocardial infarction is classically
conducted with serial biomarkers during 8 to 24
hours.
What question this study addressed
Whether 2 high-sensitivity troponin (hs-cTnT)
values at 0 and 1 hour can rapidly classify patients
into 3 groups: no acute myocardial infarction, acute
myocardial infarction, and indeterminate.
What this study adds to our knowledge
Use of hs-cTn assays at presentation and 1 hour later
in a population with a 17% rate of acute myocardial
infarction classiﬁed 63% of patients as having no
acute myocardial infarction, with a 99.1% negative
predictive value (95% conﬁdence interval 98.2% to
99.7%); 14% as having acute myocardial infarction,
with a positive predictive value of 77% (95%
conﬁdence interval 70.4% to 83.0%); and 22.5% as
having an indeterminate classiﬁcation after 1 hour of
testing.
How this is relevant to clinical practice
This study validated previous work that serial high-
sensitivity troponin values can rapidly help determine
likelihood of acute myocardial infarction.Importance
High-sensitivity cardiac troponin (hs-cTn) assays, which
allow measurement of even low cTn concentrations with
high precision, have been shown to provide high diagnostic
accuracy for acute myocardial infarction already at
presentation.7-14 In parallel, several early-rule-out strategies
have been developed. These include the use of very low
concentrations of hs-cTn,12,15-17 as well as the combination
of cTn concentrations at 0 and 2 hours with a clinical
score.18-20 Limitations of these approaches include that
they do not provide guidance for rule-in and that rule-out
is possible only in 10% to 40% of patients.12,15-20
Accordingly, the high-sensitivity cardiac troponin T
(hs-cTnT) 0-hour/1-hour algorithm has received substantial
attention.10,13 This algorithm uses hs-cTnT blood
concentrations at presentation and their absolute changes
within 1 hour to triage patients. It was reported to achieve a
very high negative predictive value for acute myocardial
infarction in the rule-out zone, to achieve a high positive
predictive value in the rule-in zone, and to be very effective bylume 68, no. 1 : July 2016triaging approximately 75% of patients presenting with
suspected acute myocardial infarction to the ED to either rule-
out or rule-in classiﬁcations.10,13Obviously, successful external
validation in a global and meticulous multicenter study is
mandatory before such a novel approach can be considered for
widespread implementation into routine clinical practice.21
Goals of This Investigation
The aim of this international multicenter study,
therefore, was to externally validate the diagnostic accuracy
of the hs-cTnT 0-hour/1-hour algorithm for rapid rule-out
and rule-in of acute myocardial infarction and thereby
evaluate its suitability for routine clinical care.
MATERIALS AND METHODS
Study Design
The High Sensitivity Cardiac Troponin T Assay for
Rapid Rule-out of Acute Myocardial Infarction (TRAPID-
AMI) trial was a prospective international multicenter
diagnostic study conducted at 12 sites on 3 continents (see
STARD checklist in Appendix E1, available at http://www.
annemergmed.com).
Selection of Participants
Patients presenting to the ED with symptoms suggestive of
acute myocardial infarction (such as acute chest pain and
angina pectoris) with an onset or maximum of discomfort or
pain within the previous 6 hours were identiﬁed by study
personnel and recruited after written informed consent had
been obtained. A threshold of fewer than 6 hours was chosen to
enrich the study population with the particularly challenging
early presenters.7-9 Patients with renal failure requiring long-
term hemodialysis; those with trauma, cardioversion,
deﬁbrillation, or thrombolytic therapy before inclusion;
individuals receiving coronary artery bypass grafting within the
last month or hospitalized for acute myocardial infarction
within the last 3weeks; andpregnant andbreastfeedingwomen
were excluded. To allow the study blood draw to be performed
as quickly as possible, deﬁnite interpretation of the initial ECG
was not required before inclusion. Accordingly, patients with
ST-segment elevationmyocardial infarction (STEMI)werenot
excluded by the protocol. The study was carried out according
to the principles of the Declaration of Helsinki and approved
by the local ethics committees.
Patients underwent an initial clinical assessment that
included clinical history, physical examination, 12-lead
ECG, pulse oximetry, standard blood tests (including local
cTn assays), and chest radiograph in accordance with local
protocols. Treatment of patients was left at discretion of
the attending physician. Standard data were collected on
study-speciﬁc case report forms.Annals of Emergency Medicine 77
Figure 1. Hs-cTnT 0-hour/1-hour algorithm. Values for hs-cTnT are shown in nanograms per liter.
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(Roche Diagnostics, Penzberg, Germany) and sensitive
cardiac troponin I ultra (s-cTnI-ultra) (Siemens Healthcare,
Tarrytown,NY)were collected in ethylenediaminetetraacetic
acid plasma tubes at presentation to the ED after written
informed consent was obtained. To ensure that the ﬁrst
study blood draw was performed within a short time from
ED presentation, this period was required to be either
within 45 minutes of presentation to the ED or less than
45 minutes after the ﬁrst routine blood draw. Additional
samples were collected after 1 hour (30 min) (n¼1,282),
2 hours (30 min) (n¼1,158), and 4 to 14 hours (30
min) (n¼1,073). After centrifugation, samples were frozen
at –80C (112F) until assayed in a blinded fashion with
the Elecsys 2010 (Roche Diagnostics) and the ADVIA
Centaur immunoassay system (Siemens Healthcare) in a
core laboratory. For hs-cTnT, limit of blank and limit of
detection have been determined to be 3 and 5 ng/L,
respectively. An imprecision corresponding to 10%
coefﬁcient of variation was reported at 13 ng/L; the 99th
percentile of a healthy reference population, at 14 ng/L.22
The s-cTnI-ultra assay is reported to have a limit of
detection of 6 ng/L, a 99th percentile cutoff point of
40 ng/L, and a coefﬁcient of variation of less than 10% at
30 ng/L.7,9,11
None of the study blood results were available to the
treating physician. The results of s-cTnI-ultra, but not
those of hs-cTnT, were available to the adjudicating
cardiologists.
The hs-cTnT 0-hour/1-hour algorithm10,13 uses hs-
cTnT blood concentrations at presentation and their
absolute changes within 1 hour to triage patients to rule-
out status, the observational zone, or rule-in status
(Figure 1): patients with hs-cTnT below 12 ng/L and
D1 hour below 3 ng/L to rule-out status, hs-cTnT at least
52 ng/L or D1 hour at least 5 ng/L to rule-in status, and the
remaining patients to the observational zone. The
combination of the level at presentation with absolute
changes within 1 hour was chosen because of the added
value of 1-hour changes and the superiority of absolute
versus relative changes. The speciﬁc cutoff values were data-
driven from the initial derivation cohort.10,11,1378 Annals of Emergency MedicineOutcome Measures
To determine the ﬁnal diagnosis for each patient,
adjudication of ﬁnal diagnoses was performed by a
dedicated group of cardiologists selected for the Clinical
Event Committee of this study (Appendix E2, available
online at http://www.annemergmed.com) according to the
universal deﬁnition of acute myocardial infarction.4 Each
patient was adjudicated by 2 independent cardiologists.
Adjudicators reviewed all available medical records
(including patient history; physical examination results;
results of laboratory testing, including levels of s-cTnI-
ultra, local cTn obtained before the ﬁrst or after the last
blood draw for the study if available, creatinine, cystatin C,
free hemoglobin [to quantify hemolysis], and NT-proBNP;
radiologic imaging; ECG; echocardiography; cardiac stress
test; and lesion severity and morphology in coronary
angiography) pertaining to the patient from ED
presentation to 30-day follow-up. Discrepancies were
solved by discussion with a third cardiologist. Interrater
reliability was assessed by documenting the number of
patients with mismatch in the ﬁnal diagnosis of acute
myocardial infarction by the 2 adjudicating cardiologists,
which required involvement of a third cardiologist.
The s-cTnI-ultra assay was chosen for the adjudication
to achieve complete blinding to hs-cTnT levels during the
study period in the ED. This assay was the best-validated
sensitive cTn assay available at study start, with early
diagnostic accuracy similar to that of the hs-cTnT
assay.7,9,11
Acute myocardial infarction was deﬁned and s-cTnI-
ultra levels interpreted as recommended in current
guidelines.2,3,23 In brief, acute myocardial infarction was
diagnosed when there was evidence of myocardial necrosis
in a clinical setting, with a signiﬁcant increase or decrease of
s-cTnI level consistent with myocardial ischemia. The 99th
percentile (40 ng/L) was used as the cutoff for myocardial
necrosis. An absolute s-cTnI-ultra change of at least
20 ng/L during the study period was used to deﬁne a
signiﬁcant increase or decrease.11 Other predeﬁned
diagnostic groups included unstable angina; other cardiac
disease including myocarditis, takotsubo cardiomyopathy,
acute heart failure, or tachyarrhythmias2; noncardiacVolume 68, no. 1 : July 2016
Figure 2. Patient ﬂow diagram.
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myocardial infarction was excluded but the evaluation was
considered insufﬁcient for a clear alternative diagnosis.
Secondary outcome measures included mortality at
30 days and 1 year. Mortality at 30 days was predeﬁned as
an additional outcome measure to evaluate the possible
appropriateness of early discharge in patients assigned as
ruled out. After hospital discharge, patients were contacted
after 1 week, 30 days, 3 months, and 12 months by
telephone calls or in written form. Information about
death was furthermore obtained from the national registry
on mortality, the hospital’s diagnosis registry, and the
family physician’s records. If the patient could not be
contacted directly, we contacted their primary care
physician.
Primary Data Analysis
Continuous variables are described by mean  SD or
median with interquartile range; categorical variables, by
numbers and percentages. The negative predictive value
and sensitivity for acute myocardial infarction of the
hs-cTnT 0-hour/1-hour rule-out rule were the primary
outcome measures. Secondary outcome measures included
the positive predictive value and speciﬁcity of the hs-cTnT
0-hour/1-hour rule-in rule, the percentage of patients
assigned to the observational zone. Predeﬁned subgroups
included patients presenting very early (chest pain onset
<median) to document whether the hs-cTnT 0-hour/
1-hour algorithm achieved a negative predictive value in
this delicate patient subgroup comparable to that in theVolume 68, no. 1 : July 2016overall cohort because here another early rule-out strategy
had been shown to have a lower negative predictive value.17
Sensitivity analysis with data removed for patients
presenting with STEMI was performed to correct for a
possible bias introduced by the inclusion of patients with
STEMI because cTn and therefore the hs-cTnT 0-hour/
1-hour algorithm is considered not necessary in its early
management. To provide further support for the selection
of the 1-hour point for the second measurement of hs-
cTnT, the combination of the hs-cTnT baseline level with
the 1-hour change was compared with the baseline level
alone, as well as with the combination of the baseline level
with the 2-hour point by quantifying diagnostic accuracy
by the area under the receiver operating characteristics
curve (AUC) (Table E2, available online at http://www.
annemergmed.com). Mortality during follow-up according
to the classiﬁcation provided by the predeﬁned hs-cTnT
0-hour/1-hour algorithm was plotted in Kaplan-Meier
curves to further examine the suitability of many of the
patients in the rule-out zone for early discharge and
outpatient management. All statistical analyses were
performed with R 3.0.1 (R Foundation for Statistical
Computing) and SAS 9.3 (SAS Institute, Inc., Cary, NC).
RESULTS
Characteristics of Study Subjects
From August 2011 to June 2013, 1,458 patients were
enrolled, of whom 1,282 were eligible for analysis
(Figure 2). Baseline characteristics are shown in Table 1.
Median time from chest pain onset or peak to EDAnnals of Emergency Medicine 79
Table 1. Baseline characteristics of the patients.*
Characteristic All Patients (n[1,282) Rule in (n[184) Observe (n[285) Rule out (n[813)
Age, y 62 (50–74) 69 (56–78) 74 (65–81) 56 (47–66)
Male patient 805 (62.8) 131 (71.2) 206 (72.3) 468 (57.6)
Risk factors
Hypertension 805 (62.8) 135 (73.4) 238 (83.5) 432 (53.1)
Diabetes 270 (21.1) 46 (25.0) 102 (35.8) 122 (15.0)
Hypercholesteremia 139 (10.8) 26 (14.1) 34 (11.9) 79 (9.7)
Current smoking 288 (22.8) 43 (23.8) 40 (14.1) 205 (25.7)
History of smoking 468 (37.1) 75 (41.4) 139 (48.9) 254 (31.9)
History
Previous coronary intervention 388 (30.3) 53 (28.8) 136 (47.7) 199 (24.5)
PCI (unknown as PCI) 284 (22.2) 34 (12.0) 91 (32.0) 159 (56.0)
CABG 104 (8.1) 19 (10.3) 45 (15.8) 40 (4.9)
Previous myocardial infarction 319 (24.9) 48 (26.1) 115 (40.4) 156 (19.2)
Stable angina pectoris 148 (11.5) 26 (14.1) 51 (17.9) 71 (8.7)
Unstable angina pectoris 164 (12.8) 30 (16.3) 55 (19.3) 79 (9.7)
Congestive heart failure 107 (8.3) 23 (12.5) 59 (20.7) 25 (3.1)
Time from chest pain onset/peak to presentation, h 1.8 (1.0–2.9) 2 (1.1–3.0) 1.9 (1.2–3.1) 1.7 (1.0–2.9)
Time from chest pain onset to ﬁrst study blood draw, h 3.4 (2.1–6.0) 3.5 (2.4–6.0) 3.4 (2.2–6.0) 3.4 (2.0–6.0)
Creatinine clearance† ml/min/1.73m2 81 (65–97) 73 (54–91) 68 (52–83) 86 (72–101)
Systolic blood pressure, mm Hg 141 (127–157) 141 (126–160) 142 (127–160) 141 (127–155)
Diastolic blood pressure, mm Hg 81 (72–90) 81 (70–92) 80 (70–89) 81 (73–91)
Pulse rate, beats/min 76 (66–88) 78 (68–92) 78 (66–90) 76 (65–86)
ECG
Rhythm
Atrial ﬁbrillation 92 (7.2) 16 (8.7) 53 (18.6) 23 (2.8)
Sinus 1,148 (89.5) 159 (86.4) 218 (76.5) 771 (94.8)
Other rhythm 42 (3.3) 9 (4.9) 14 (4.9) 19 (2.3)
Left ventricular hypertrophy 65 (5.1) 9 (4.9) 28 (9.8) 28 (3.4)
Complete LBBB 36 (2.8) 11 (6.0) 17 (6.0) 8 (1.0)
Complete RBBB 55 (4.3) 9 (4.9) 27 (9.5) 19 (2.3)
Paced ventricular complex 23 (1.8) 8 (4.3) 15 (5.3) 0
Pathologic Q waves 119 (9.3) 28 (15.2) 38 (13.3) 53 (6.5)
ST-segment elevation‡ 60 (4.7) 17 (9.2) 14 (4.9) 29 (3.6)
ST-segment depression 164 (12.8) 47 (25.5) 66 (23.2) 51 (6.3)
T inversion 184 (14.4) 46 (25.0) 71 (24.9) 67 (8.2)
Normal ECG 1,148 (89.6) 159 (86.4) 218 (76.5) 771 (94.8)
HEART score§ 3 (2–5) 4 (3–5) 5 (4–6) 3 (2–4)
Low risk (3) 618 (48.2) 52 (28.2) 46 (16.1) 520 (64.0)
Intermediate risk (4–6) 557 (43.4) 114 (62.0) 197 (69.1) 246 (30.3)
High risk (7) 48 (3.7) 11 (6.0) 25 (8.8) 12 (1.5)
Previous medication
Aspirin 657 (51.2) 110 (59.8) 188 (66.0) 359 (44.2)
Anticoagulants 193 (15.1) 39 (21.2) 75 (26.3) 79 (9.7)
Diuretic 314 (24.5) 61 (33.2) 123 (43.2) 130 (16.0)
ACE inhibitor 383 (29.9) 58 (31.5) 121 (42.5) 204 (25.1)
Angiotensin-receptor blocker 204 (15.9) 34 (18.5) 67 (23.5) 103 (12.7)
b-Blocker 488 (38.1) 78 (42.4) 162 (56.8) 248 (30.5)
Calcium antagonist 248 (19.3) 43 (23.4) 84 (29.5) 121 (14.9)
Nitrates 390 (30.4) 65 (35.3) 120 (42.1) 205 (25.2)
Other platelet aggregation inhibitor 180 (14.0) 29 (15.8) 60 (21.1) 91 (11.2)
Antiarrhythmic drug 65 (5.1) 12 (6.5) 33 (11.6) 20 (2.5)
Other cardiac medication 554 (43.2) 80 (43.5) 185 (64.9) 289 (35.5)
PCI, Percutaneous coronary intervention; CABG, coronary artery bypass grafting; LBBB, left bundle branch block; RBBB, right bundle branch block; ACE, angiotensin-converting
enzyme.
*Values are No. (%) or medians (interquartile range).
†Using the Modiﬁcation of Diet in Renal Disease equation.36
‡Including patients with STEMI, takotsubo cardiomyopathy, perimyocarditis, left ventricular hypertrophy, and early repolarization.
§HEART (History, ECG, Age, Risk Factors, Troponin) score was missing for 59 patients (35 rule-out, 7 rule-in, and 17 observe status). For this reason, the percentages in brackets
for the 3 categories do not sum to 100% because it is the percentage of all 1,282 patients.
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Table 2. Twotwo tables and calculation of negative and positive
predictive value, as well as sensitivity and speciﬁcity for the rule-
out and rule-in of myocardial infarction.
A, Algorithm classiﬁcation versus adjudicated diagnosis.
Algorithm Classiﬁcation AMI Non-AMI Total
Rule-out status 7 806 813
Observational zone 64 221 285
Rule-in status 142 42 184
Total 213 1,069 1,282
AMI, Acute myocardial infarction.
B, Negative and positive predictive value.
Diagnostic Test
Performance Measures Estimate, % 95% CI Counts
NPV 99.14 98.23–99.65 806/813
PPV 77.17 70.42–83.03 142/184
NPV, Negative predictive value; PPV, positive predictive value.
C, Sensitivity and speciﬁcity.*
Diagnostic Test
Performance Measures Estimate, % 95% CI Counts
Sensitivity in the rule-out zone 96.71 93.35–98.67 206/213
Speciﬁcity in the rule-in zone 96.07 94.73–97.15 1,027/1,069
*Sensitivity: true positive/diseased (AMI). The rule-out zone deﬁnes patients with no
AMI according to the 0-hour/1-hour hs-cTnT algorithm. Only patients in this zone are
ruled out. Accordingly, for the rule-out it is irrelevant whether patients are in the
observational zone or the rule-in zone, and both zones are combined. True
positive¼206; diseased (AMI)¼213; sensitivity¼96.71%. Speciﬁcity: true negative/
non-diseased (non-AMI). The rule-in zone deﬁnes patients with AMI according to the 0-
hour/1-hour hs-cTnT algorithm. Only patients in this zone are ruled in. Accordingly, for
the rule-in it is irrelevant whether patients are in the observational zone or the rule-out
zone, and both zones are combined. True negative¼1,027; non-diseased (non-AMI)
1,069; speciﬁcity¼96.07%.
Mueller et al Diagnosing Myocardial Infarction With High-Sensitivity Cardiac Troponin Tpresentation was 1.8 hours (interquartile range 1.0 to 2.9
hours), and median time from chest pain onset to ﬁrst
study blood draw was 3.4 hours (interquartile range 2.1 to
6 hours).
The adjudicated ﬁnal diagnosis was acute myocardial
infarction for 213 patients (17%; 21 patients with
acute STEMI), unstable angina for 167 (13%), cardiac
symptoms of origin other than coronary artery disease for
113 (9%), noncardiac symptoms for 288 (22%), and
symptoms of unknown origin for 501 (39%). Interrater
reliability in regard to acute myocardial infarction was
very high, with concordant ﬁnal diagnoses among the 2
adjudicating cardiologists for 97.7% of patients and the need
for involvement of a third cardiologist for 2.3% of patients.
Applying the predeﬁned hs-cTnT 0-hour/1-hour
algorithm, 813 (63.4%) patients could be classiﬁed to
rule-out status, 184 (14.4%) patients were classiﬁed to rule-
in status, and 285 (22.2%) patients were classiﬁed to
observational zone status (Table 2, Figure 3). Among the 813
patients classiﬁed to rule-out status, 806 had an adjudicated
diagnosis other than acute myocardial infarction, and 7
patients received a diagnosis of acute myocardial infarction.
The characteristics of these patients are described in Table 3.
This resulted in a negative predictive value and sensitivity of
99.1% (95% conﬁdence interval [CI] 98.2% to 99.7%) and
96.7% (95% CI 93.4% to 98.7%), respectively, for acute
myocardial infarction in the rule-out zone. Accordingly, the
miss rate was 0.9% in the rule-out zone. The negative
predictive value was comparable in various predeﬁned
subgroups, including very early presenters (Figure 4). Among
the 184 patients classiﬁed to rule-in status, 142 received an
adjudicated diagnosis of acute myocardial infarction and
42 received another diagnosis. This resulted in a positive
predictive value and speciﬁcity of 77.2% (95% CI 70.4% to
83.0%) and 96.1% (95%CI 94.7% to 97.2%), respectively,
for acute myocardial infarction in the rule-in zone. The
most common other diagnoses in the rule-in zone were
myocarditis (n¼4), unstable angina (n¼4), takotsubo
cardiomyopathy (n¼3), heart failure (n¼3), arrhythmia
(n¼3), and symptoms of unknown origin (n¼16).
Among the 285 patients classiﬁed to the observational
zone, 64 received an adjudicated diagnosis of acute
myocardial infarction, resulting in a prevalence of 22.5%
in this group.
Sensitivity analysis, in which data for STEMI patients
(n¼21) were removed, revealed similar ﬁndings (Table E2
and Figure E1, available online at http://www.
annemergmed.com).
A single cutoff value for hs-cTnT (14 ng/L, the 99th
percentile of healthy individuals) at presentation resulted in
a sensitivity and negative predictive value of 88.7% (95%Volume 68, no. 1 : July 2016CI 83.7% to 92.6%) and 97.3% (95% CI 96.0% to
98.3%), respectively, and a speciﬁcity and positive
predictive value of 81.5% (95% CI 79.0% to 83.8%) and
48.8% (95% CI 43.8% to 53.9%), respectively. The AUC
for the combination of hs-cTnT at presentation with
1-hour levels and 1-hour absolute change (0.95 [95% CI
0.93 to 0.97]) was signiﬁcantly higher compared with the
AUC of hs-cTnT at presentation (0.91 [95% CI 0.88 to
0.93]) and comparable to the combination of hs-cTnT at
presentation with 2-hour levels and 2-hour absolute change
(0.95 [95% CI 0.93 to 0.96]). Models with adjustment for
age, sex, previous acute myocardial infarction, and renal
function revealed similar ﬁndings (Appendix E3, available
online at http://www.annemergmed.com).
Cumulative 30-day mortality was 0.1%, 0.7%, and
2.7% in patients classiﬁed as rule-out, observational zone,
and rule-in (Figure 5). This pattern continued up to a
follow-up of 365 days, with cumulative mortality
rates of 0.7%, 9.6%, and 8.9%, respectively. AlthoughAnnals of Emergency Medicine 81
Figure 3. Performance of the 0-hour/1-hour algorithm for diagnosis of acute myocardial infarction, using hs-cTnT levels. 0h¼hs-
cTnT at presentation to the ED. Delta 1h¼absolute change of hs-cTnT within the ﬁrst hour. Sensitivity and speciﬁcity as reported
here were calculated according to Table 2C, with the observational zone patients considered as correctly classiﬁed.
Diagnosing Myocardial Infarction With High-Sensitivity Cardiac Troponin T Mueller et alapproximately 50% of deaths in the rule-in group were due
to cardiac causes, the majority in the observational group
were due to noncardiac causes (Table E3, available online
at http://www.annemergmed.com).
LIMITATIONS
Potential limitations of the current study merit
consideration. First, our study was conducted with ED
patients with symptoms suggestive of acute myocardial
infarction. Additional studies—for example, in patients
presenting to a family physician—are required to learn
whether this algorithm would have a similar performance in
patients with lower pretest probability. Second, the data
presented were obtained in an observational diagnostic
study, in which the hs-cTnT 0-hour/1-hour algorithm was
compared against a centrally adjudicated ﬁnal diagnosis.
Treating physicians were blinded to the investigational hs-
cTnT results and patients were not managed in accordance
with these results. The successful validation of the hs-cTnT
0-hour/1-hour algorithm in this study now warrants
applying it prospectively for clinical decisionmaking.
Further work should focus on the evaluation of the cost-
effectiveness of the algorithm when implemented in
practice. Third, this diagnostic study required written
informed consent and had predeﬁned inclusion and
exclusion criteria, as well as a study-speciﬁc case report
form. Patient enrollment therefore required the presence of
dedicated research personnel in the ED at the patients’
presentation. Accordingly, invariably the rate of enrollment
was lower than in a recent registry15 and, as in nearly all
clinical studies, resulted in an underrepresentation of
patients presenting during the night. Fourth, our ﬁndings
may slightly underestimate the true negative predictive
value of the hs-cTnT 0-hour/1-hour algorithm because a
threshold of chest pain onset of fewer than 6 hours (versus
fewer than 12 hours in the Advantageous Predictors in82 Annals of Emergency MedicineAcute Coronary Syndrome Evaluation [APACE] study) was
chosen to enrich the study population with the particularly
challenging early presenters.7-9 Fifth, we cannot comment
on the performance of the hs-cTnT 0-hour/1-hour
algorithm in patients with terminal kidney failure requiring
dialysis; those receiving cardioversion, deﬁbrillation, or
thrombolysis before inclusion; those undergoing coronary
artery bypass grafting within the last month or hospitalized
for acute myocardial infarction within the last 3 weeks; or
pregnant and breastfeeding women because such patients
were excluded from this study.DISCUSSION
This international multicenter study was performed to
prospectively validate the performance of the recently
developed hs-cTnT 0-hour/1-hour algorithm for rapid rule-
out and rule-in of acute myocardial infarction. This study
differs in 4 key aspects from the initial pilot study.10,13,14
First, it had global representation of patients with 12 sites in
the United States, Europe, and Australia, whereas the
APACE study recruited in Europe only. Second, we enriched
the study population with challenging early presenters by
requiring chest pain onset to be fewer than 6 hours at
presentation compared with 12 hours in APACE. Third,
this study aimed to maximize internal and external validity
by recruiting patients presenting with acute chest pain
irrespective of their ECG ﬁndings, whereas patients with
STEMI were excluded in previous analyses from APACE.
Fourth, to have the most stringent methodology and make
the adjudicated ﬁnal diagnosis completely independent of all
components of the hs-cTnT 0-hour/1-hour algorithm, serial
testing for s-cTnI-ultra complemented all other clinical
information, including coronary angiography in TRAPID-
AMI, whereas serial testing for hs-cTnT complemented all
other clinical information in APACE.Volume 68, no. 1 : July 2016
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Figure 4. Forest plot indicating negative predictive value of the
0-hour/1-hour algorithm in study subgroups.
Mueller et al Diagnosing Myocardial Infarction With High-Sensitivity Cardiac Troponin T
Volume 68, no. 1 : July 2016We found that accurate rule-out and rule-in seems
to be feasible much more rapidly than suggested in
current American Heart Association/American College of
Cardiology1 guidelines in the majority of patients. We
report 7 major novel ﬁndings.
First, the negative predictive value for acute myocardial
infarction in the rule-out zone, deﬁned only on hs-cTnT
levels at presentation and the change within 1 hour, was
99.1%. Thereby, the hs-cTnT 0-hour/1-hour algorithm in
TRAPID-AMI had a negative predictive value similar to
that observed in the APACE pilot study.10,13 The negative
predictive value was also comparable to that achieved
with an accelerated diagnostic protocol combining the
Thrombolysis in Myocardial Infarction score with hs-cTn
levels at 0 and 2 hours18-20 and seemed higher compared
with the dual-marker approach combining cTn with
copeptin.24-28 For example, the negative predictive value of
hs-cTnI combined with a very low cutoff value of copeptin
(9 pmol/L) was 95% to 97% when the ﬁnal diagnosis was
adjudicated with hs-cTn.28
Second, in TRAPID-AMI only approximately half of
patients with missed acute myocardial infarction exhibited
late increasing hs-cTnT levels.29 The other half never
showed an elevation in hs-cTnT but did show a small time-
dependent dynamic change in s-cTnI-ultra, indicating lower
agreement among these widely used tests in the low end of
themeasuring range, as expected.30,31 All missed adjudicated
acute myocardial infarctions were small, and most patients
with them received a clinical discharge diagnosis of unstable
angina, not acute myocardial infarction, indicating that fullAnnals of Emergency Medicine 83
A B
Figure 5. Kaplan-Meier curves for cumulative mortality according to classiﬁcation provided by the hs-cTnT 0-hour/1-hour algorithm.
Kaplan-Meier curves displaying cumulative mortality during A, 30 days of follow-up, and B, 365 days of follow-up in all chest pain
patients (n¼1,282) according to the classiﬁcation into rule-out (green), observational zone (orange), and rule-in (red) provided by
the hs-cTnT 0-hour/1-hour algorithm.
Diagnosing Myocardial Infarction With High-Sensitivity Cardiac Troponin T Mueller et alclinical assessment allowed appropriate identiﬁcation of
them irrespective of the biomarker results. Coronary
revascularization was performed in only 1 of these 7 patients.
Because the hs-cTnT 0-hour/1-hour algorithm should
always be used in conjunction with full clinical assessment,
including patient history and examination, the 12-lead (or
16-lead) ECG, and other diagnostic investigations, the
negative predictive value of the combination of the 0-hour/
1-hour algorithm and all other clinical information can be
expected to further increase and fulﬁll the high safety
standards required in this setting.1,2,23,32
Third, the positive predictive value for acute
myocardial infarction in the rule-in zone was 77%. Patients
in the rule-in zone with diagnosis other than acute
myocardial infarction did have conditions that usually still
require early admission, and most require coronary
angiography for accurate diagnosis, including takotsubo
cardiomyopathy, myocarditis, and unstable angina.1,2
Therefore, the immediate clinical consequence of being
assigned the rule-in zone would likely be early admission,
eg, to the coronary care unit, and in general early
coronary angiography, unless clinical assessment would
indicate another obvious condition associated with acute
cardiomyocyte damage, eg, heart failure, tachyarrhythmia,
hypertensive crisis.3,4 The rule-in zone of this hs-cTnT
0-hour/1-hour algorithm is more precisely deﬁned than
in the European Society of Cardiology hs-cTn 3h-
algorithm.1,2 Because the rule-in of acute myocardial84 Annals of Emergency Medicineinfarction in patients with mild elevations in hs-cTn is
often challenging for clinicians,3,23 it is a key advantage of
this hs-cTnT 0-hour/1-hour algorithm to provide more
detailed guidance in this challenging setting.
Fourth, by assigning patients to 3 groups (rule-out,
observe, rule-in) the hs-cTnT 0-hour/1-hour algorithm is
fundamentally different from other strategies that just
deﬁne the early discharge group. Overall, the hs-cTnT
0-hour/1-hour algorithm assigned 78% of patients a
deﬁnite process (either rule-out or rule-in), with only 22%
of patients remaining in the observational zone. Thereby,
the hs-cTnT 0-hour/1-hour algorithm seemed to be even
more complete and more effective in the early triage of
acute chest pain patients than other important emerging
early triage strategies in similar study populations.18,20,24-28
This difference is at least partly explained by the fact that
the latter exclusively selects patients for rule-out, but does
not provide guidance for rule-in.
Fifth, the hs-cTnT 0-hour/1-hour algorithm was
superior to the interpretation using a single cutoff value of
14 ng/L for hs-cTnT, both in regard to negative and
positive predictive value. This documents the superiority of
the 0-hour/1-hour algorithm versus the use of a single
measurement of hs-cTnT for both ruling out and ruling in
acute myocardial infarction.
Sixth, the diagnostic accuracy of the combination of hs-
cTnT at presentation and 1-hour change was signiﬁcantly
higher than the presentation value only and comparable toVolume 68, no. 1 : July 2016
Mueller et al Diagnosing Myocardial Infarction With High-Sensitivity Cardiac Troponin Tthe combination of hs-cTnT at presentation with the
2-hour point. This ﬁnding provides further support for the
selection of the 1-hour point for the second measurement
of hs-cTn. One hour seems to be an excellent compromise
between speed and accuracy when using hs-cTnT.
Seventh, cumulative 30-day mortality was 0.1% in
patients assigned to the rule-out zone, further documenting
the suitability of many of these patients for early discharge
and outpatient management.
Our ﬁndings extend and corroborate recent results
obtained in the APACE pilot study.10,13 It is reassuring
that despite 4 relevant methodological differences, ﬁndings
were comparable in both studies (APACE: negative
predictive value 100%, 95% CI 99% to 100%; positive
predictive value 76%, 95% CI 69% to 82%).
Although patients assigned to the observational zone had
lower 30-daymortality than those assigned to the rule-in zone,
1-year mortality was high and comparable in both groups.
Therefore, patients assigned to the observational zone need
careful clinical evaluation and individualized management to
identify and, if possible, treat the underlying condition.
Management may include coronary angiography in patients
with a high clinical suspicion of acute myocardial infarction,
coronary computed tomography angiography in patients with
low to intermediate likelihood for acutemyocardial infarction,
a third hs-cTn sample at 3 or 6 hours for many patients, or no
further immediate diagnostic testing when complete clinical
evaluation has established, for example, rapid atrial ﬁbrillation
or hypertensive crisis as the ﬁnal diagnosis.1-3,33,34
It might be possible to further simplify and accelerate the
rule-out in patients with very low (undetectable) hs-cTn
levels. Indeed, recent evidence from 3 diagnostic studies and
a meta-analysis indicated a high negative predictive value for
acute myocardial infarction of very low (undetectable) hs-
cTn levels even without any serial sampling.12,15-17
The assessment of patients with acute chest pain in the
ED is not limited to the rule-out or rule-in of acute
myocardial infarction. Although unstable angina has
recently been shown to be a less serious disorder, with no
beneﬁt from routine early revascularization or aggressive
antiplatelet therapy1,2,23,35 compared with acute
myocardial infarction, many patients who experience it
may still beneﬁt from hospitalization. In addition,
pulmonary embolism and aortic dissection always warrant
attention as alternative diagnoses.
In conclusion, the hs-cTnT 0-hour/1-hour algorithm
performs well for early rule-out and rule-in of acute
myocardial infarction.
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Table E1. Additional contributors to the TRAPID-AMI study.*
Investigator Institution Name City, Country
Raphael Twerenbold, MD Department of Cardiology and Cardiovascular Research Institute Basel
University Hospital Basel
Basel, Switzerland
Hugo A. Katus, MD, PhD University of Heidelberg Heidelberg, Germany
Steffen Popp, MD Department of Emergency and Critical Care Medicine
Klinikum Nuremberg
Nuremberg, Germany
Miquel Santalo-Bel, MD, PhD Department of Emergency Medicine, Institut d’Investigacions Biomèdiques Sant Pau Barcelona, Spain
Richard M. Nowak, MD, MBA Henry Ford Health System Detroit, MI
Daniel Horner, MD University of Manchester Manchester, UK
Alberto Dolci, MD University of Milan Medical School Milan, Italy
Martina Zaninotto University Hospital of Padova Padua, Italy
Alessandro Manara, MD Cliniques Universitaires St-Luc and Université Catholique de Louvain Brussels, Belgium
Sylvie Menassanch-Volker, PhD Roche Diagnostics International Ltd Rotkreuz, Switzerland
Jochen Jarausch, PhD Roche Diagnostics Germany (formerly) Penzberg, Germany
Christian Zaugg, PhD Roche Diagnostics International Ltd Rotkreuz, Switzerland
*These study investigators and sponsor contributors also receive credit for this work.
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APPENDIX E1
STARD checklist (modiﬁed from Ann Intern Med. 2003;138:40-44)
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D, Sensitivity and speciﬁcity excluding 21 STEMI patients.*
Diagnostic Test
Performance Measures Estimate, % 95% CI Counts
Sensitivity in the rule-out zone 96.35 92.63–98.52 185/192
Speciﬁcity in the rule-in zone 96.07 94.73–97.15 1,027/1,069
*Sensitivity: True positive/diseased (AMI). The rule-out zone deﬁnes patients with no
AMI according to the 0-hour/1-hour hs-cTnT algorithm. Only patients in this zone are
ruled out. Accordingly, for the rule-out it is irrelevant whether patients are in the
observational zone or the rule-in zone, and both zones are combined. True
positive¼185; diseased (AMI)¼192; sensitivity¼96.35%. Speciﬁcity: True negative/
non-diseased (non-AMI). The rule-in zone deﬁnes patients with AMI according to the
0-hour/1-hour hs-cTnT algorithm. Only patients in this zone are ruled in. Accordingly,
for the rule-in it is irrelevant whether patients are in the observational zone or the
rule-out zone, and both zones are combined. True negative¼1,027; non-diseased
(non-AMI)¼1,069; speciﬁcity¼96.07%.
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Clinical Endpoints Committee (CEC)
Uppsala Clinical Research Center, Uppsala, Sweden
Chairman of the CEC: Claes Held, MD, PhD
CECTeam:UlrikaBodén,RN, andPernillaHolmgren,RN
CEC cardiologists:
Evangelos Giannitsis, MD
Michael Christ, MD
Christoph Varenhorst, MD
Kai Eggers, MD
Tomasz Baron, MD
Tomas Jernberg, MD
Richard Müller-Brunotte, MD
Nina Johnston, MD
Christina Christersson, MD
Birgitta Jönelid, MD
Christer Lidell, MD
Ziad Hijazi, MD
Axel Åkerblom, MD
Emil Hagström, MD
Bengt-Olov Fredlund, MD
Camilla Svanberg, MD
Richard Body, MB ChB, PhDTable E2. Twotwo tables excluding STEMI patients.
A, Classiﬁcation of STEMI patients.
Algorithm Classiﬁcation STEMI
Rule-out status 0
Observational zone 2
Rule-in status 19
Total 21
B, Algorithm classiﬁcation versus adjudicated diagnosis excluding 21
STEMI patients.
Algorithm Classiﬁcation AMI Non-AMI Total
Rule-out status 7 806 813
Observational zone 62 221 283
Rule-in status 123 42 165
Total 192 1,069 1,261
C, Negative and positive predictive value excluding 21 STEMI patients.
Diagnostic Test
Performance Measures Estimate, % 95% CI Counts
NPV 99.14 98.23–99.65 806/813
PPV 74.55 67.19–81.00 123/165
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Multivariate modeling for classiﬁcation of acute
myocardial infarction
Multivariate models were calculated with logistic
regression, with “AMI¼yes/no” as response variable. Values
of hs-cTnT were transformed by logarithm when
considered as covariates. Hs-cTnT Ds were considered as
absolute (non-negative) differences of serial measurements.
Ten-fold cross validation was applied to avoid overﬁtting
in multivariate modeling. AUC values were calculated
according to the cross-validated logistic regression scores to
assess the classiﬁcation power of each model:
 Reference model:
B Multivariate model including hs-cTnT at presentation
(T0), hs-cTnT at 1 hour after presentation (T1), andD
(T0, T1) as covariates.
This acted as the reference model because it contains
the same covariates for classiﬁcation as the TRAPID-
AMI 0-hour/1-hour algorithm.
 Competitor models:
B Univariate models using hs-cTnT values at single
blood draws (univariate approaches do not require
logistic regression and cross validation).
B Multivariate models using hs-cTnT values at various
serial blood draws (including values at 2 hours after
presentation [T2]), according to D values or baseline
characteristics.
P-values were calculated for each competitor model
versus the reference model, comparing AUC values (using
the method by de Long, et al1) and applying Holm’s
procedure for multiplicity adjustment:Volume 68, no. 1 : July 2016
able E3. Numbers (and percentages) of cardiac and noncardiac
death cases, per 0-hour/1-hour algorithm class.
Cardiac
Death
(%)
Noncardiac
Death (%)
Death
(%)
Within 7 days/N(available)[1,272
Ruled out 1 (0.1) 0 1 (0.1)
Ruled in 1 (0.5) 0 1 (0.5)
Observational zone 0 1 (0.4) 1 (0.4)
Total 2 (0.2) 1 (0.1) 3 (0.2)
Within 30 days/N(available)[1,271
Ruled out 1 (0.1) 0 1 (0.1)
Ruled in 4 (2.2) 1 (0.5) 5 (2.7)
Observational zone 0 2 (0.7) 2 (0.7)
Total 5 (0.4) 3 (0.2) 8 (0.6)
Within 3 mo/N(available)[1,264
Ruled out 1 (0.1) 1 (0.1) 2 (0.3)
Ruled in 4 (2.2) 4 (2.2) 8 (4.4)
Observational zone 1 (0.4) 7 (2.5) 8 (2.8)
Total 6 (0.5) 12 (0.9) 18 (1.4)
Within 1 y/N(available)[1,082
Ruled out 1 (0.1) 4 (0.6) 5 (0.7)
Ruled in 7 (4.3) 8 (4.9) 15 (9.3)
Model
Covariates/
Predictor AUC Individual CI
P
Value
Reference model T0, T1, D 0.947 0.929–0.965
Univariate
competitor
models
T0 0.905 0.881–0.929 <.001
T1 0.933 0.913–0.952 .04
T2 0.947 0.930–0.963 .997
Multivariate
competitor
models
T0, T1, D, age,
sex, previous
AMI, eGFR <60
0.948 0.931–0.966 .79
T0, T2, D 0.959 0.945–0.973 .28
T0, T1, T2, Ds 0.956 0.941–0.971 .28
eGFR, Estimated glomerular ﬁltration rate.
Mueller et al Diagnosing Myocardial Infarction With High-Sensitivity Cardiac Troponin TResults showed that the reference model performed
superior to univariate models with hs-TnT values at
T0 or T1 only. This supports combining T0 and T1
values (as done in the TRAPID-AMI/APACE
algorithm).
The multivariate model including T0 and T2 values had
accuracy comparable to that of the reference model.Figure E1. Performance of the 0-hour/1-hour algorithm after the e
ED. Delta 1h¼absolute change of hs-cTnT within the ﬁrst hour. Sen
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